EE03128B1 - Kudede plasminogeenaktivaatori parandatud terapeutiliste omadustega glükosüleerimisvariandid - Google Patents

Kudede plasminogeenaktivaatori parandatud terapeutiliste omadustega glükosüleerimisvariandid

Info

Publication number
EE03128B1
EE03128B1 EE9400401A EE9400401A EE03128B1 EE 03128 B1 EE03128 B1 EE 03128B1 EE 9400401 A EE9400401 A EE 9400401A EE 9400401 A EE9400401 A EE 9400401A EE 03128 B1 EE03128 B1 EE 03128B1
Authority
EE
Estonia
Prior art keywords
plasminogen activator
tissue plasminogen
therapeutic properties
improved therapeutic
glycosylation variants
Prior art date
Application number
EE9400401A
Other languages
English (en)
Inventor
Allan Keyt Bruce
F. Bennett William
F. Paoni Nicholas
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of EE03128B1 publication Critical patent/EE03128B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EE9400401A 1992-06-03 1994-11-17 Kudede plasminogeenaktivaatori parandatud terapeutiliste omadustega glükosüleerimisvariandid EE03128B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89421392A 1992-06-03 1992-06-03

Publications (1)

Publication Number Publication Date
EE03128B1 true EE03128B1 (et) 1998-10-15

Family

ID=25402765

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400401A EE03128B1 (et) 1992-06-03 1994-11-17 Kudede plasminogeenaktivaatori parandatud terapeutiliste omadustega glükosüleerimisvariandid

Country Status (20)

Country Link
US (1) US5612029A (et)
EP (2) EP0786257B1 (et)
JP (1) JP3559559B2 (et)
AT (2) ATE246000T1 (et)
AU (1) AU664469B2 (et)
CA (1) CA2129660C (et)
DE (3) DE10199044I2 (et)
DK (2) DK0643772T3 (et)
EE (1) EE03128B1 (et)
ES (2) ES2107041T3 (et)
FI (1) FI117940B (et)
GE (1) GEP20012448B (et)
GR (1) GR3024806T3 (et)
HK (2) HK1000449A1 (et)
IL (1) IL105883A (et)
LU (1) LU90800I2 (et)
NL (1) NL300050I2 (et)
NZ (1) NZ253556A (et)
PT (1) PT786257E (et)
WO (1) WO1993024635A1 (et)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0728210B1 (en) * 1993-11-12 2005-04-13 Gilead Sciences, Inc. Thrombin mutants
US7060484B1 (en) 1993-11-12 2006-06-13 Gilead Sciences, Inc. Polypeptides and coagulation therapy
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5510330A (en) † 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
DE4423574A1 (de) * 1994-07-05 1996-01-11 Boehringer Mannheim Gmbh Nicht-glykosylierte Plasminogenaktivator-Derivate und ihre Verwendung bei erhöhtem Blutungsrisiko
US5945432A (en) * 1995-12-22 1999-08-31 The University Of Vermont And State Agricultural College Thrombolytic agents and thienopyridine derivatives in acute stroke
AU2660397A (en) * 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US6083715A (en) * 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
WO1999023115A1 (en) * 1997-10-31 1999-05-14 Eli Lilly And Company Glycosylated obesity protein analogs
US6242473B1 (en) 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
PL204011B1 (pl) 1999-11-04 2009-12-31 Genentech Inc Sposób monitorowania sposobu oczyszczania przez usuwanie aktywatora plazminogenu z próbki
US20030036181A1 (en) * 2000-06-30 2003-02-20 Okkels Jens Sigurd Peptide extended glycosylated polypeptides
CN1578650A (zh) * 2001-11-06 2005-02-09 马克西姆医药公司 治疗感染性疾病的组合物
IL162083A0 (en) * 2001-11-26 2005-11-20 Genentech Inc Catheter composition and uses thereof
US7084118B2 (en) 2002-02-22 2006-08-01 Genentech, Inc. Combination treatment with t-PA variant and low molecular weight heparin
US20060105387A1 (en) * 2002-08-30 2006-05-18 Prior Christopher P Transferrin fusion proteins libraries
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
WO2006023530A2 (en) * 2004-08-16 2006-03-02 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
JP2009507467A (ja) * 2005-06-02 2009-02-26 アベスタゲン リミテッド 生物工学処理形態の組織プラスミノーゲン活性化因子の生成方法
US7932084B2 (en) * 2005-09-08 2011-04-26 University Of Virginia Patent Foundation Methods and compositions for growing adipose stem cells
EP2010117A4 (en) * 2006-04-12 2010-12-01 Massachusetts Inst Technology COMPOSITIONS AND METHODS FOR ADHESION INHIBITION
JP2009533458A (ja) * 2006-04-14 2009-09-17 マサチューセッツ インスティテュート オブ テクノロジー 神経系の可塑性を媒介する分子経路の同定および変調
AU2007290277B2 (en) 2006-08-29 2013-04-11 Genentech, Inc. Use of tenecteplase for treating acute ischemic stroke
CA2665475A1 (en) * 2006-10-06 2008-05-22 University Of Virginia Patent Foundation Methods and compositions useful for diabetic wound healing
EP2086571A2 (en) 2006-11-07 2009-08-12 Genentech, Inc. Tissue plasminogen activator variant uses
KR100834561B1 (ko) 2006-12-08 2008-06-02 가톨릭대학교 산학협력단 크링글 도메인 1 및 2로 이루어진 비-글리코실화 재조합단백질, 그 제조 방법 및 이를 포함하는 조성물
EP2289542A1 (en) 2009-08-31 2011-03-02 PAION Deutschland GmbH Treatment of neurological or neurodegenerative disorders
EP2289541A1 (en) 2009-08-31 2011-03-02 PAION Deutschland GmbH Treatment of neurological or neurodegenerative disorders
US20130122076A1 (en) * 2011-11-11 2013-05-16 Mathew Gelfand Transdermal Patch Having Ultrasound Transducer for Administering Thrombolytic Reagents to Patients Having a Protein Misfolding Disease
IN2015MN00047A (et) * 2012-07-05 2015-10-16 Hadasit Med Res Service
EP2928480B1 (en) 2012-12-05 2019-09-25 National Jewish Health Treatment for airway cast obstruction
CN103159860B (zh) * 2013-04-07 2014-09-24 旭华（上海）生物研发中心有限公司 重组组织型纤溶酶原激活剂及其制备方法与用途
WO2015023830A1 (en) 2013-08-14 2015-02-19 Stc.Unm Treatment and prevention of stroke and other neurological disorders
CN107073292B (zh) * 2014-11-03 2021-07-02 溶栓科学有限责任公司 用于安全和有效的溶栓的方法和组合物
AU2018214222C1 (en) 2017-02-03 2021-08-05 Acticor Biotech Inhibition of platelet aggregation using anti-human GPVI antibodies
EP3624832A1 (en) 2017-05-16 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute ischemic stroke
US11154596B2 (en) 2017-06-16 2021-10-26 Thrombolytic Science, Llc Methods for thrombolysis
US20210238605A1 (en) 2018-06-15 2021-08-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pi3kc2b inhibitors for the preservation of vascular endothelial cell barrier integrity
WO2021148439A1 (en) 2020-01-21 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stimulating cerebrovascular function
WO2021249974A1 (en) 2020-06-09 2021-12-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Fucoidan-functionalized polysaccharide particles with t-pa for targeted thrombolytic therapy
WO2023156683A1 (en) 2022-02-21 2023-08-24 Acticor Biotech Treatment of cardiovascular diseases using anti-human gpvi antibodies

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NL8003402A (nl) 1980-06-11 1982-01-04 Leuven Res & Dev Vzw Nieuwe plasminogeen-activator en farmaceutisch preparaat met trombolytische werking.
IL68561A (en) 1982-05-05 1991-01-31 Genentech Inc Preparation of polypeptide with human tissue plasminogen activator function,processes for making it,and dna and transformed cell intermediates thereof
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
WO1984001960A1 (en) * 1982-11-11 1984-05-24 Beecham Group Plc Pharmaceutically active compounds
EP0112122B1 (en) * 1982-12-14 1991-08-28 South African Inventions Development Corporation Plasminogen activator
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4658830A (en) * 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
US4753879A (en) * 1984-08-27 1988-06-28 Biogen N.V. Modified tissue plasminogen activators
EP0178105B1 (en) * 1984-10-01 1997-04-02 Genzyme Corporation Recombinant DNA techniques and the products thereof
DE3537176C2 (de) * 1984-10-18 1994-06-09 Zymogenetics Inc Gewebeplasminogenaktivator und Verfahren zu seiner Herstellung
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
EP0201153A3 (en) * 1985-02-09 1987-10-07 Beecham Group Plc Modified enzyme and process for its preparation
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
ES8801374A1 (es) * 1985-04-04 1988-01-01 Beecham Group Plc Un procedimiento para preparar un activante de plasminogeno.
DE3613390C2 (de) * 1985-04-22 2001-10-11 Genentech Inc Einkettige Human-Gewebeplasminogen-Aktivator (t-PA)-Mutanten, kodierende DNA, Expressionsvektor, Mikroorganismus, Zellkultur und pharmazeutische Zusammensetzung
NZ216306A (en) * 1985-05-28 1989-10-27 Wellcome Found Pharmaceutical compositions containing tissue plasminogen activator
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
US4960702A (en) * 1985-09-06 1990-10-02 Codon Methods for recovery of tissue plasminogen activator
DE3687255T2 (de) * 1985-09-10 1993-05-06 Eisai Co Ltd Einen gewebe-plasminogen-aktivator enthaltende zusammensetzung.
GB8528321D0 (en) * 1985-11-18 1985-12-24 Ciba Geigy Ag Modified fibrinolytic agents
KR950000303B1 (ko) * 1985-12-20 1995-01-13 디 엎죤 캄파니 조직 플라스미노겐 활성화 인자(tpa) 상사체를 제조하는 방법
US5501853A (en) 1985-12-23 1996-03-26 Chiron Corporation Peptide plasminogen activators
DK43387A (da) * 1986-01-29 1987-07-30 Beecham Group Plc Fibrinolytisk enzym
EP0293394B2 (en) * 1986-01-31 2003-10-29 Genetics Institute, LLC Novel thrombolytic proteins
IE81073B1 (en) 1986-03-18 2000-01-12 Genentech Inc Modified human tissue-type plasminogen activator and its preparation
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
AU7090687A (en) 1986-04-02 1987-10-08 Beecham Group Plc Modified tissue-type plasminogen activators
PT84589B (en) * 1986-04-02 1989-05-09 Beecham Group Plc Process for preparing a fibrinolytic enzyme
PT84588B (en) 1986-04-02 1989-05-09 Beecham Group Plc Process for preparing a fibrinolytic enzyme
DE3643158A1 (de) * 1986-04-21 1987-11-19 Boehringer Mannheim Gmbh Gewebs-plasminogen-aktivator(tpa) - derivat und seine herstellung
JPH0761266B2 (ja) * 1986-07-03 1995-07-05 株式会社ミドリ十字 変異ヒトプロウロキナ−ゼ
DK345087A (da) * 1986-07-11 1988-01-12 Novo Industri As Modificeret vaevsplasminogenaktivator
GB8619098D0 (en) * 1986-08-05 1986-09-17 Wellcome Found Combination
EP0266032A1 (en) * 1986-08-29 1988-05-04 Beecham Group Plc Modified fibrinolytic enzyme
WO1988005081A2 (en) * 1986-12-30 1988-07-14 Cetus Corporation Novel plasminogen activator
GB8705377D0 (en) * 1987-03-07 1987-04-08 Beecham Group Plc Compounds
DK275788A (da) * 1987-05-22 1989-02-03 Zymogenetics Inc Fibrinolytiske proteiner
DK302288A (da) * 1987-06-04 1989-02-03 Zymogenetics Inc Vaevsplasminogenaktivator med modificeret kringledomaene
NO179874C (no) * 1987-06-04 1997-01-02 Zymogenetics Inc Fremgangsmåte for fremstilling av en t-PA-analog, DNA-sekvens som koder for t-PA-analogen, samt ekspresjonsvektor omfattende DNA-sekvensen og vertcelle omfattende denne
SE8702562L (sv) * 1987-06-18 1988-12-19 Kabigen Ab Nya fibrinolytiska enzymer
KR960015610B1 (ko) * 1987-06-22 1996-11-18 제네틱스 인스티튜트, 인코포레이티드 신규의 혈전붕괴 단백질의 제조방법
JPH02504102A (ja) * 1987-06-30 1990-11-29 ジェネンテク，インコーポレイテッド 血管障害治療のための改良法
US4935237A (en) 1988-03-21 1990-06-19 Genentech, Inc. Processes for the preparation of t-PA mutants
JPH03500002A (ja) * 1987-07-06 1991-01-10 ジェネティックス・インスチチュート・インコーポレーテッド 新規な血栓崩壊蛋白
AU1893988A (en) * 1987-07-13 1989-01-19 Collaborative Research Inc. Nonglycosylated plasminogen activator and method of preparation
CA1308377C (en) 1987-08-21 1992-10-06 Henry Berger, Jr. Complex of polyethyleneglycol and tissue plasminogen activator
IL88247A0 (en) 1987-11-06 1989-06-30 Genentech Inc Novel human tissue-type plasminogen activator variant
US5225540A (en) 1988-04-26 1993-07-06 Du Pont Merck Pharmaceutical Company Monoclonal antibodies to tissue plasminogen activator (t-pa) which prolong its functional half-life
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
IL90146A (en) 1988-05-20 1994-10-07 Genentech Inc Glycosylation derivatives of tissue plasminogen activator
US5342616A (en) * 1988-06-20 1994-08-30 The Wellcome Foundation Limited Method of administering tissue plasminogen activator
GB8815135D0 (en) 1988-06-24 1988-08-03 British Bio Technology Proteins & nucleic acids
DK395288D0 (da) * 1988-07-15 1988-07-15 Novo Industri As Proteiner
US5258180A (en) * 1988-09-02 1993-11-02 Genetech, Inc. Tissue plasminogen activator having fibrin specific properties and deletion of amino acids 466-970, compositions and methods of treatment
US5108901A (en) * 1988-09-02 1992-04-28 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5041376A (en) * 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
US5304482A (en) * 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
EP0462207B1 (en) * 1989-03-06 2001-02-07 Board Of Regents, The University Of Texas System T-pa mutants resistant to inhibition by their cognate inhibitors
DE394538T1 (de) 1989-04-28 1991-04-11 Rhein Biotech Ges. Fuer Biotechnologische Prozesse Und Produkte Mbh, 4000 Duesseldorf Hefezellen der schwanniomyces-gattung.
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
US5087572A (en) 1989-12-01 1992-02-11 Genentech, Inc. Dna encoding human plasminogen modified at the cleavage site
US5366730A (en) * 1989-12-20 1994-11-22 Boehringer Mannheim Gmbh Stabilized compositions having human tissue type plasminogen activator enzymatic activity
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
US5246850A (en) * 1990-07-31 1993-09-21 Genentech, Inc. DNA molecules encoding human tissue plasminogen activator variants with decreased clearance, vectors, and host cells
CA2086835C (en) 1990-07-31 2002-04-02 Bruce A. Keyt Tissue plasminogen activator variants with decreased clearance
US5242688A (en) * 1990-12-24 1993-09-07 Eli Lilly And Company Method of treating thromboembolic disorders by administration of diglycosylated t-pa variants

Also Published As

Publication number Publication date
DE69312493T2 (de) 1998-01-15
DE69333127T2 (de) 2004-05-06
JP3559559B2 (ja) 2004-09-02
HK1000449A1 (en) 2004-03-05
DE10199044I2 (de) 2006-02-09
DK0786257T3 (da) 2003-10-06
FI117940B (fi) 2007-04-30
CA2129660A1 (en) 1993-12-09
WO1993024635A1 (en) 1993-12-09
FI943632A0 (fi) 1994-08-04
IL105883A (en) 2003-04-10
AU4397393A (en) 1993-12-30
EP0786257B1 (en) 2003-07-30
ES2203668T3 (es) 2004-04-16
PT786257E (pt) 2003-12-31
DE69333127D1 (de) 2003-09-04
CA2129660C (en) 2005-06-28
DE69312493D1 (de) 1997-09-04
EP0786257A1 (en) 1997-07-30
FI943632A (fi) 1994-10-04
NL300050I1 (nl) 2001-10-01
AU664469B2 (en) 1995-11-16
GEP20012448B (en) 2001-05-25
ATE246000T1 (de) 2003-08-15
EP0643772B1 (en) 1997-07-23
EP0643772A1 (en) 1995-03-22
HK1001190A1 (en) 1998-05-29
US5612029A (en) 1997-03-18
DE10199044I1 (de) 2002-02-21
IL105883A0 (en) 1993-10-20
GR3024806T3 (en) 1998-01-30
LU90800I2 (fr) 2001-10-08
NZ253556A (en) 1995-11-27
NL300050I2 (nl) 2001-11-01
ATE155816T1 (de) 1997-08-15
JPH07507448A (ja) 1995-08-24
ES2107041T3 (es) 1997-11-16
DK0643772T3 (da) 1998-02-02

Similar Documents

Publication Publication Date Title
EE03128B1 (et) Kudede plasminogeenaktivaatori parandatud terapeutiliste omadustega glükosüleerimisvariandid
BE2013C033I2 (et)
IL80659A (en) Modified tissue plasminogen activators,their preparation and pharmaceutical compositions containing them
IL89500A0 (en) Human tissue plasminogen activator variants and processes
DK0383417T3 (da) Flagmusespyt-plasminogenaktivator v-PAalfa1
DK0542869T3 (da) Vævsplasminogenaktivatorvarianter med nedsat udskillelse
AU7696087A (en) Recombinant human tissue plasminogen activator composition
GR3015094T3 (en) Tissue plasminogen activator substitution variant.
NO880831D0 (no) Rekombinant human vevsplasminogen-aktivatorblanding.

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231